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1. Introduction 
Methylglyoxal bis(guanylhydrazone) (MGBG) is an 
antiproliferative compound used clinically in cancer 
chemotherapy [l-3]. Earlier the mechanism of action 
of MGBG was often related to the metabolism of 
polyamines, especially because its antiproliferative 
effects were counteracted by spermidine 141: it was 
only in [5] that MGBG was shown to be a remarkably 
potent and specific inhibitor of eukaryotic S-adenosyl- 
L-methionine decarboxylase (EC 4.1 .1.50), an enzyme 
directly involved in the synthesis of spermidine and 
spermine. Since then the compound has been widely 
used to produce intracellular polyamine deprivation 
in a number of experimental systems including cul- 
tured cells and animal tissues (for references ee [6]). 
In all systems employed, the growth-inhibitory effect 
of MGBG can be prevented by PM levels of spermidine 
and spermine [6]. This finding has been taken as 
evidence indicating that the antiproliferative action 
exerted by MGBG is mediated through an inhibition 
of intracellular accumulation of spermidine and 
spermine. However, a straightforward interpretation 
of these studies is complicated by the fact that MGBG, 
spermidine and spermine appear to compete for a 
common cellular uptake system [7,8]. It is thus 
possible that the prevention of MGBG-induced 
toxicity by polyamines could partly result from a 
reduction of the intracellular concentration of the 
drug, and is not necessarily due to a normalization of 
cellular polyamine pattern. With the possible excep- 
tion of a few studies [9 ,101, the effect of polyamines 
on the intracellular concentrations of MGBG has not 
been checked properly. This apparently is related to 
the lack of sensitive methods for determination of 
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minute amounts of MGBG under cell culture condi- 
tions. 
We have now developed a sensitive (pmol order) 
enzymic method for rapid determination of MGBG 
concentrations in cultured cells and in extracts of 
animal tissues. The method is based upon the findings 
that MGBG is a potent competitive inhibitor of 
putrescine-activated adenosylmethionine decarboxylase 
[5,1 1,121 and an equally effective noncompetitive 
inhibitor of mammalian diamine oxidase (EC 1.4.3.6) 
[ 11 ,131. Using partially purified enzymes, MGBG con- 
tents from 25-250 pmol (adenosylmethionine decar- 
boxylase) or from 50-400 pmol (diamine oxidase) 
could be easily measured. 
When cultured cells (human lymphocytic leukemia 
cells and Ehrlich ascites carcinoma cells) were grown 
in the presence of PM levels of MGBG, the compound 
was so effectively taken up by the cells, that a 
600-l 500-fold gradient across the cell membrane was 
soon established. That is, in cells exposed to 5-10 PM 
MGBG the drug reached 4-6 mM intracellularly, which 
is probably sufficiently high to directly influence 
variety of cellular reactions and structures. Further- 
more, the reversal of the antiproliferative effects of 
MGBG by spermidine and spermine was closely asso- 
ciated with strikingly decreased rug levels (by 
85-90s) in cells cultured in the presence of MGBG 
and the polyamines. 
2. Material and methods 
2.1. Cells 
Human acute lymphocytic leukemia cells (type B) 
(kindly donated by Dr Leif Andersson) and Ehrlich 
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ascites carcinoma cells (adapted to growth in suspen- tissue homogenates were kept in a boiling water bath 
sion cultures) were cultured in RPM1 1640 medium for 10 min in order to inactivate any endogenous 
(Orion Diagnostica. Helsinki) supplemented with 10% adenosylmethionine decarboxylase (that can occur in 
human serum (Finnish Red Cross Transfusion Service, substantial amounts in cells exposed to MGBG due to 
Helsinki), L-glutamine (7 mM) and penicillin and strep- the stabilization of the enzyme). Any precipitate 
tomycin _@O pg/ml each). formed during heating was removed by centrifugation. 
3.2. Partial purification of adenosylmethionitle decar- 
boxylase and diamine oxidase 
Adenosylmethlonine decarboxylase from baker’s 
yeast was extracted and purified through ammonium 
sulphate fractionation by the method in [14]. The 
dialyzed ammonium sulphate fraction was used in 
the MGBG assays. Diamine oxidase from day I 1 rat 
fetuses was likewise refined through ammomum 
sulphate fractionation [IS] and used after dialysis. 
Aliquots (2 or 3 different dilutions) of the boiled 
homogenates were added to the sdenosyhnethionme 
decarboxylase [ 171 or diamine oxidase [ 1 S] assay 
system. A series of standards containing known 
amounts of MGBG were run in parallel. The amount 
of MGBG in unknown samples was obtained from a 
standard curve plotted according to [19], i.e., the 
plot of MGBG concentration versus the reciprocal 
of initial velocity. 
2.3. Chemicals 
S-Adenosyl-L-[ 1 -14C] methionine was prepared 
enzymically essentially as m [ 161. [ 1 .4-‘4C]Putrescine 
(spec. radioact. 116 Ci/mol) was obtained from the 
Radiochemical Centre, Amersham, Bucks. Methyl- 
glyoxal bis(guanylhydrazone) was the product of 
Aldrich-Europe (Beerse). 
The recovery of MGBG, added prior to the boiling, 
was virtually 100% in cell homogenates and 80% in 
tissue homogenates (due to large precipitations in 
protein-rich samples). 
3. Results 
2.4. Analytical methods 
Cell densities were measured in an electronic 
particle counter (Coulter Electronics Ltd). Cell 
diameters (for determination of the cellular volumes) 
were measured after standardization of the counter 
with latex particles as recommended in the instruction 
manual for the Coulter counter. 
The activities of adenosylmethionine decarboxylase 
and of diamine oxidase were assayed as in [ 17 ,181. 
Adenosylmethionine decarboxylase was always assayed 
m the presence of 2.5 mM putrescine. 
Regression lines were computed by the least squares 
method. 
As shown in fig.1, the sensitivity of the method 
allowed the determination of the drug starting from 
75 or 50 pmol. The upper limit for linearity of 
adenosylmethionine decarboxylase assay was 
-250 pm01 (fig.la). while with diamine oxidase 
(fig. 1 b) assay somewhat higher concentrations of 
MGBG (<400 pmol) could be accurately measured. 
When human lymphocytic leukemia cells were 
exposed to PM levels of MGBG, the compound was 
effectively concentrated mtracellularly. The determi- 
nation of the cellular concentrations of MGBG either 
2.5. Determination of AlGBG in cultured cells and rat 
tissues 
Leukemia cells and Ehrlich ascites carcinoma cells 
were harvested by low speed centrifugation, washed 
once with 2 ml physiological saline and suspended in 
distilled water. The cells were disintegrated ultra- 
sonically by a Branson Sonifier (3 X 5 s, half-maximum 
power). Rat tissues were homogenized with 3 vol. 
Tris-HCl buffer (pH 7.4) containing I mM dithio- 
threitol. 
Prior to the determination of MGBG, the cell or 
1:ig.l. Standard curves for the determination of MGBG with 
adenosylmethionine decarbosylase (a, AMDC) assay or 
diamine oxidase (b, DAO) assay. 
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Table 1 
Uptake of MGBG by human lymphocytic leukemia cells 
MGBG m Cellular uptake of MGBG 
medium (PM) ~ 
pmol/l O6 cells 
___- 
AMDC DA0 
1 619? 148 770 f 101 
5 1940 * 210 2441 f 70 
10 2380 + 338 2350 + 298 
Intracellular level (~J1ll) 
AMDC DA0 
1480 + 350 1850 + 480 
4660 * 500 5860 + 340 
5710 + 810 5630 + 710 
The cells were grown in the presence of the indicated concentrations of MGBG for 
24 h. The concentrations of MGBG were measured by both adenosylmethionine 
decarboxylase (AMDC) and diamine oxidase (DAO) assays as in the text. The 
values are means (? SEM) of 4 determinations 
with adenosylmethionine decarboxylase or diamine 
oxidase gave comparable results (table 1). When grown 
in the presence of 1 yM MGBG, the drug (assuming 
even distribution) in human leukemia cells reached 
1.5-l 35 mM intracellularly, i.e., >I SOO-fold the 
concentration of the drug in the culture medium 
(table 1). In the presence of 10 PM MGBG, the intra- 
cellular level of the drug approached 6 mM that 
represents a concentration gradient of 600-fold 
across the cell membrane (table 1). 
The leukemia cells appeared to take up the drug 
by a saturable transport process, since the intracellular 
MGBG concentration hardly increased when the extra- 
cellular concentration of the drug was raised from 
5-10 FM (table 1). This is in reasonable agreement 
with earlier studies with L1210 cells, where the initial 
velocities of the transport of labeled MGBG were 
measured [S]. Although the initial velocities were 
not measured, the uptake process appeared to be 
rather slow occurring over a period of days. 
In analogy with the leukemia cells, Ehrlich ascites 
tumor cells likewise effectively concentrated the drug 
intracellularly. An intracellular level of 4 mM was 
reached in cells exposed to 5 PM MGBG for 48 h 
(table 2). This concentration of MGBG produced a 
distinct antiproliferative effect in Ehrlich ascites cells, 
as also seen in table 2. Inclusion of 10 PM putrescine 
together with MGBG only slightly reduced the cellular 
concentration of the drug, while similar concentra- 
tions of spermidine and spermine decreased the cel- 
lular MGBG to 10-l%% of that found in cells grown 
in the presence of MGBG alone (table 2). Spermidine 
and spermine added directly to the assay mixture of 
MGBG did not have any effect on the determination 
Table 2 
Uptake of MGBG by Ehrlich ascites carcinoma cells in the 




(ctM) MGBG (PM) 
Cell density 
(X lO+/ml) 
None 0 0.892 
MGBG 5 4050 0.424 
MGBG + 5 
putrescine 10 3620 0.482 
MGBG + 5 
spermidine 10 728 0.880 
MGBG + 5 
spermine 10 525 0.920 
The cells were grown in the absence or presence of MGBG 
with or without polyamines for 48 h. The concentration of 
MGBG was measured with adenosylmethionine decarboxylase 
assay as in the text 
Table 3 
Concentration of MGBG in some rat tissues and blood 
plasma after a single injection of MGBG 
Tissue MGBG 
(pmol/g) 
Liver 0.790 i 0.015 
Kidney 0.410 + 0.034 
Spleen 0.180 f 0.010 
Plasma 0.024 t 0.001 
Rats (av. wt 275 g) received an intraperitoneal injection of 
49 pmol MGBG 3 h before death. MGBG was determined in 
tissue extracts with the adenosylmethionine decarboxylase 
assay as in the text. The values are means (+ SEM) obtained 
from 4 rats 
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of the drug. Interestingly, the latter reduction of 
cellular MGBG content by spermidine and spermine 
was closely associated with the disappearance of the 
MGBG-induced antiproliferative effect (table 2). 
A single intraperitoneal injection of 49 pmol 
MGBG into adult rats produced relatively high drug con. 
centrations in various tissues (table 3). The highest 
concentration of MGBG (-0.8 mM) was found in the 
liver, whereas in the plasma it was much lower (24 PM) 
(table 3). 
4. Discussion 
The cellular actions of MGBG are related to the 
metabolism of polyamines at least at two different 
levels : 
(i) The drug apparently inhibits the transport of 
higher polyamines and vice versa [7,8]; 
(ii) It profoundly depresses the synthesis of spermi- 
dine and spermine by blocking the decarboxyla- 
tion of adenosylmethionine [S]. 
The Ki for MGBG as a competitive inhibitor of 
eukaryotic adenosylmethionine decarboxylase is 
<l PM [5,11,12]. MGBG in cell cultures at l-10 PM 
are most used [6], producing a marked decrease in 
cellular spermidine and spermine contents associated 
with a distinct inhibition of cell growth. However, 
even though these concentrations of drug in the 
culture media appear to be only slightly higher than 
those needed for more or less complete inhibition of 
adenosylmethionine decarboxylase in vitro, the situa- 
tion is strikingly different inside the cell, where the 
drug may be as high as 5 mM (tables 1,2). Comparable 
intracellular concentrations of MGBG have also been 
reported [IO] using an indirect assay method for the 
drug. 
In analogy with the competition of MGBG with 
higher polyamines for a common transport system 
[7,8], it is probable. even likely, that mM intracellular 
levels of MGBG may influence the binding of poly- 
amines (likewise occurring at mM levels to some cel- 
lular components and structures. In fact, at these con- 
centrations MGBG has been shown to exert a number 
of effects in vitro. These include interaction with 
eukaryotic DNA and inhibition of template activity 
[20], inhibition of RNA polymerase activity [21] and 
inhibition of oxidative phosphorylation and cell 
respiration [22]. It thus seems possible, that in cells 
exposed to only PM levels of MGBG, the intracellular 
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content of the drug is nevertheless ufficiently high to 
produce comparable effects also in vivo. 
The observed close parallelism between the reduc- 
tion of intracellular MGBG concentration and the 
reversal of its growth-inhibitory effects by spermidine 
and spermine, but not by putrescine. warrants more 
systematic studies to support the view that MGBG 
exerts its antiproliferative action exclusively through 
prevention of polyamine biosynthesis. 
In addition to cultured cells. possessing such a 
remarkable concentrating capacity, this method is 
also suitable for determination of MGBG in tissue 
extracts. It could also be used clinically to monitor 
plasma concentrations of MGBG so as to achieve better 
control of cytostatic chemotherapy. 
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